Refractory Hypoglycaemia in Hepatocellular Carcinoma Treated with TACE Leading to Tumour Lysis Syndrome- A Double Trouble

Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. Hypoglycaemia is a well-established paraneoplastic manifestation of HCC. Cytoreduction by surgery or Transarterial Chemoembolisation (TACE) has been effective treatment options in such cases when conservative treatment f...

Full description

Bibliographic Details
Main Authors: Saurabh kumar, Ishita B Sen, Vivek Vij, Ashish Singhal, Ajitabh Srivastava
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2022-01-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://www.jcdr.net/articles/PDF/15923/52274_CE(Ra1)_F(SS)_PF1(SC_SS)_PFA(SC_KM)_PN(KM).pdf
Description
Summary:Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. Hypoglycaemia is a well-established paraneoplastic manifestation of HCC. Cytoreduction by surgery or Transarterial Chemoembolisation (TACE) has been effective treatment options in such cases when conservative treatment fails. Tumour Lysis Syndrome (TLS) is an oncological emergency following treatment of malignancies with high cell turnover and can be seen in liver-directed therapy in the form of both ablative therapies and transarterial therapies for HCC. Authors present a rare case of 65-year-old male, with HCC presented with symptoms of refractory hypoglycaemia which was managed by TACE procedure with further patient developing TLS which was medically managed.
ISSN:2249-782X
0973-709X